Pharmacokinetics of oseltamivir among pregnant and nonpregnant women

被引：53

作者：

Beigi, Richard H. ^{[1
,2
]}

Han, Kelong ^{[3
]}

Venkataramanan, Raman ^{[3
]}

Hankins, Gary D. ^{[4
]}

Clark, Shannon ^{[4
]}

Hebert, Mary F. ^{[5
]}

Easterling, Thomas ^{[5
]}

Zajicek, Anne ^{[6
]}

Ren, Zhaoxia ^{[6
]}

Mattison, Donald R. ^{[7
]}

Caritis, Steve N. ^{[1
,2
]}

机构：

[1] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Med Ctr,Div Reprod Infect Dis, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Med Ctr,Div Maternal Fetal Med, Pittsburgh, PA 15213 USA

[3] Univ Pittsburgh, Sch Med, Dept Pathol, Dept Pharmaceut Sci,Sch Pharm, Pittsburgh, PA USA

[4] Univ Texas Med Branch, Dept Obstet & Gynecol, Div Maternal Fetal Med, Galveston, TX USA

[5] Univ Washington, Sch Med, Dept Pharm & Obstet & Gynecol, Seattle, WA USA

[6] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Obstet & Pediat Pharmacol Branch, Ctr Res Mothers & Children, NIH, Bethesda, MD USA

[7] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD USA

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2011年 / 204卷 / 06期

基金：

美国国家卫生研究院;

关键词：

influenza; oseltamivir; pregnancy; treatment; 2009; H1N1; INFLUENZA; PANDEMIC INFLUENZA; HOSPITALIZATIONS; INFECTION; EPIDEMIC;

D O I：

10.1016/j.ajog.2011.03.002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of pregnancy, including increased renal filtration and secretion, may increase the clearance of oseltamivir carboxylate. Sixteen pregnant women taking oseltamivir for prophylaxis or treatment of suspected/proven influenza infection were enrolled. Twenty-three nonpregnant reproductive-age females served as the control group. The primary PK endpoint was area under the plasma concentration time curve for oseltamivir carboxylate. Pregnancy did not alter the PK parameters of the parent compound, oseltamivir. However, for oseltamivir carboxylate the area under the plasma concentration time curve was significantly lower (P = .007) and the apparent clearance significantly higher (P = .006) in pregnant women compared with nonpregnant women. Pregnancy produces lower systemic levels of oseltamivir carboxylate. Increasing the dose and/or dosing frequency of oseltamivir during pregnancy may be necessary to achieve comparable exposure in pregnant and nonpregnant women.

引用

页码：S84 / S88

页数：5

共 28 条

[1] Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach [J].